CALCULATE YOUR SIP RETURNS

Vimta Labs Released Q1 FY25 Results: PAT Margin Stood at 14.9%

Updated on: Jul 25, 2024, 5:56 PM IST
Despite a challenging internal and external environment, Vimta Labs achieved a QoQ growth in sales driven by Pharmaceutical services.
Vimta Labs Released Q1 FY25 Results: PAT Margin Stood at 14.9%
ShareShare on 1Share on 2Share on 3Share on 4Share on 5

Vimta Labs, a leading Contract Research and Testing Organisation (CRO) in India, announced its financial results for the quarter ended June 30, 2024, on July 17, 2024. The company delivered a positive performance, showcasing healthy revenue and profitability margins.

Key Financial Highlights

Total Income: ₹824 million, reflecting a stable revenue stream for the quarter.

Profitability

EBITDA: ₹252 million, with an impressive EBITDA margin of 30.6%, indicating efficient operations and cost management.

Profit Before Tax (PBT): ₹165 million, demonstrating strong profitability.

Profit After Tax (PAT): ₹123 million, translating to a PAT margin of 14.9%, highlighting the company’s ability to convert revenue into sustainable profits.

Basic Earnings Per Share (EPS): ₹ 5.5, indicating healthy shareholder value creation.

Financial Strength

Debt: Well-managed debt position with a total debt of only ₹130 million as of June 30, 2024.

Liquidity: Strong liquidity position with cash and cash equivalents standing at ₹324 million as of June 30, 2024.

Capital Expenditure (Capex): Q1 FY25 Capex spending of ₹164 million signifies ongoing investment in growth initiatives.

Debt-to-equity ratio: Notably low debt-to-equity ratio of 0.04x, indicating a financially conservative approach and a healthy balance sheet.

Commenting on results, Ms Harita Vasireddi, Managing Director, Vimta Labs Limited, said, “We are pleased to report stable business momentum with encouraging QoQ sales growth and stable EBITDA margins. Despite a challenging internal and external environment, we achieved a QoQ growth in sales, driven by Pharmaceutical services, which demonstrated sustained growth, albeit slightly tempered by the other services.

Looking ahead, we are pleased to share that our new Life Sciences facility expansion will become operational in Q2 of this financial year. This facility is expected to play a significant role in driving our growth in the coming quarters. We remain optimistic about the future and are dedicated to fostering sustainable growth.”

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.

Published on: Jul 18, 2024, 6:39 PM IST

We're Live on WhatsApp! Join our channel for market insights & updates

Open Free Demat Account!

Join our 2 Cr+ happy customers

+91
Enjoy Zero Brokerage on Equity Delivery
4.4 Cr+DOWNLOADS
Enjoy ₹0 Account Opening Charges

Get the link to download the App

Get it on Google PlayDownload on the App Store
Open Free Demat Account!
Join our 2 Cr+ happy customers